




RealRate

PHARMACEUTICAL 2020

Matinas BioPharma Holdings Inc.
Rank 162 of 362

MATINAS
BIOPHARMA



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is -144%, being 159% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	29,923
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	3,097
Liabilities, Non-Current	4,091
Other Assets	7,232
Other Compr. Net Income	-0.88
Other Expenses	0
Other Liabilities	0
Other Net Income	1,548
Property and Equipment	1,749
Research and Development	11,235
Revenues	90
Selling, General and Administrative Expense	7,776

Output Variable	Value in 1000 USD
Assets	40,240
Liabilities	7,189
Expenses	19,011
Stockholders Equity	33,052
Net Income	-17,373
Comprehensive Net Income	-17,373
Economic Capital Ratio	-144%